M20-098
99 years and younger
All genders
PURPOSE This is an extension of the M15-736 study to assess the long-term safety, tolerability and efficacy of ABBV-951 delivered as a CSCI for 24 hours daily at personally optimized therapeutic doses in patients with Parkinson's Disease.
